

## GLOBAL MARKETS FOR ORPHAN DRUGS



PHM038D  
June 2013

Shalini Shahani Dewan  
*Project Analyst*

ISBN: 1-56965-422-0

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE	2
SCOPE OF THE STUDY	2
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	3
RELATED BCC RESEARCH REPORTS	3
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL SALES OF ORPHAN DRUGS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL SALES OF ORPHAN DRUGS BY TYPE, 2010-2017 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
<i>TABLE 1 HISTORY OF ORPHAN DRUG LEGISLATION</i>	11
U.S. ORPHAN DRUG ACT	11
REASONS FOR THE ORPHAN DRUG ACT	11
OTHER LEGISLATION IN THE U.S.	12
ORPHAN DRUG PROGRAMS	12
Orphan Drug Designation Program	12
Orphan Products Grant Program	13
Pediatric Device Consortia (PDC) Grant Program	13
Humanitarian Use Device (HUD) Program	13
<i>TABLE 2 U.S. ORPHAN DRUG ACT, AMENDMENTS AND OTHER LEGISLATION</i>	13
SUCCESS OF ORPHAN DRUG ACT	14
<i>TABLE 3 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2012</i>	14
ORPHAN DRUGS: GLOBAL STATUS	14
EUROPEAN UNION	15
AUSTRALIA	16
SINGAPORE	16
JAPAN	17
TAIWAN	17
CANADA	18
BRAZIL	18
SOUTH KOREA	18
ISRAEL	18
<i>TABLE 4 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN</i>	19
CLASSIFICATION OF ORPHAN DRUGS	20
BIOLOGICAL PRODUCTS	20

<b>TOPIC</b>	<b>PAGE NO.</b>
NONBIOLOGICAL PRODUCTS	20
<i>TABLE 5 BIOLOGICAL ORPHAN DRUGS BY TRADE NAME AND INDICATION</i>	21
<i>TABLE 6 NONBIOLOGICAL ORPHAN DRUGS BY TRADE NAME AND INDICATION</i>	22
<i>TABLE 7 EXAMPLES OF ORPHAN DRUGS, INDICATIONS AND PREVALENCE OF DISEASES</i>	27
INDUSTRY OUTLOOK TOWARD ORPHAN DRUGS	27
MARKET EXCLUSIVITY	28
PRICING AND REGULATORY RESTRICTIONS ON PROFITABILITY	28
OFF-LABEL USE	28
FUTURE CHALLENGES FOR THE ODA	29
COMPANIES WITH ORPHAN DRUG APPROVALS	29
<i>TABLE 8 COMPANIES WITH MORE THAN FIVE ORPHAN DRUG APPROVALS,* 1983-2012</i>	30
ORPHAN DRUG ACCESS AND REIMBURSEMENT	31
UNITED STATES	31
EUROPE	32
CHAPTER 4 NEW PRODUCT DEVELOPMENT AND REGULATION OF ORPHAN DRUGS	34
INTRODUCTION	34
PROCESS AND APPROVAL OF ORPHAN DRUGS	35
RECENT ORPHAN DRUG APPROVALS	35
Kalydeco (Ivacaftor)	35
Carbaglu (Carglumic Acid)	35
Vpriv (Velaglucerase)	36
Pomalyst (Pomalidomide)	36
Abthrax (Raxibacumab)	36
Corifact (Factor XIII Concentrate [Human])	36
Vpriv (Velaglucerase-Alfa Injection)	36
<i>TABLE 9 ORPHAN DRUG MARKETING APPROVALS, 2008 THROUGH FEB. 2013</i>	37
RECALLS AND SAFETY ALERTS	52
<i>TABLE 10 ORPHAN DRUG SAFETY ALERTS AND RECALLS, 2008-2013</i>	52
CHAPTER 5 GLOBAL MARKET FOR ORPHAN DRUGS	56
MARKET BY TYPE	56
MARKET OVERVIEW	57
Recent Orphan Drug Approvals	58
Nplate (Romiplostim)	58
Nulojix (Belatacept)	58
Avastin (Bevacizumab)	58
Sensipar (Cinacalcet)	58
Neupogen/Imumax (filgrastim) and Neutroval (Tbo-filgrastim)	58
Gammagard Liquid (Immune Globulin Infusion [Human])	59
Multiferon (Interferon Alpha)	59
Avonex/Rebif (Interferon Beta-1a)	59
Rituxan/MabThera (Rituximab)	59
Herclon/Herceptin (Trastuzumab)	59
VariZIG (Varicella Zoster Immune Globulin)	60
Afinitor (Everolimus)	60

<b>TOPIC</b>	<b>PAGE NO.</b>
Sirturo (Bedaquiline)	60
Vidaza (Azacitidine)	60
Onfi (Clobazam)	61
NovoSeven RT (rFVIIa)	61
Sprycel (Dasatinib)	61
Gleevec/Glivec (Imatinib Mesylate)	61
Cerezyme (Imiglucerase)	61
Thalomid (Thalidomide)	62
Tasigna (Nilotinib)	62
Temodar (Temozolomide)	62
Thyrogen (Thyrotropin Alfa for Injection)	62
TOBI Podhaler (Tobramycin)	62
Topamax (Topiramate)	63
Zometa/Zomera/Aclasta/Reclast (Zoledronic or Zoledronate)	63
MARKET REVENUE	63
<i>TABLE 11 GLOBAL SALES OF ORPHAN DRUGS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	64
<i>FIGURE 1 GLOBAL SALES OF ORPHAN DRUGS BY TYPE, 2010-2017 (\$ MILLIONS)</i>	64
MARKET SHARES	64
<i>TABLE 12 GLOBAL MARKET SHARES OF MAJOR ORPHAN DRUGS BY TYPE, 2011 (%)</i>	65
<i>FIGURE 2 GLOBAL MARKET SHARES OF MAJOR ORPHAN DRUGS BY TYPE, 2011 (%)</i>	65
MARKET BY REGION	65
MARKET OVERVIEW	66
MARKET REVENUE	67
<i>TABLE 13 GLOBAL SALES OF ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	68
<i>FIGURE 3 GLOBAL SALES OF ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)</i>	68
MARKET SHARES	68
<i>TABLE 14 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY REGION, 2011 (%)</i>	69
<i>FIGURE 4 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY REGION, 2011 (%)</i>	69
Market for Biological Orphan Drugs by Region	69
<i>TABLE 15 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	70
<i>FIGURE 5 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)</i>	71
Market Shares	71
<i>TABLE 16 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)</i>	71
<i>FIGURE 6 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)</i>	71
Market for Nonbiological Orphan Drugs by Region	72
<i>TABLE 17 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	73
<i>FIGURE 7 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)</i>	74
Market Shares	74
<i>TABLE 18 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)</i>	74

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 8 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)</i>	74
MARKETS BY END USERS	75
MARKET OVERVIEW	75
Nephrology and Other Infectious Diseases	75
Oncology	76
Chronic Lymphocytic Leukemia	77
HER2-Positive Metastatic Cancer	77
Advanced Follicular Lymphoma	77
Metastatic Breast Cancer	78
HR+ and HER2/HER2- Advanced Breast Cancer	78
Metastatic Colorectal Cancer	78
Metastatic Melanoma	78
Metastatic Non-small Cell Lung Cancer	79
Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia	79
Pancreatic Neuroendocrine Tumors	80
PUA Levels in Patients with Leukemia, Lymphoma and Solid Tumor Malignancies	80
Neurological Disorders	81
Multiple Sclerosis	81
Lou Gehrig's Disease	81
Alzheimer's Disease	81
Multifocal Motor Neuropathy	81
Stem Cell Transplantation	81
Other Rare Diseases	82
Chronic Immune (Idiopathic) Thrombocytopenic Purpura	82
ANCA-Associated Vasculitis	83
Fabry Disease	83
Varicella Zoster Virus	83
Gouty Arthritis	84
Non-Transfusion-Dependent Thalassemia/Beta-Thalassemia Major	84
Cushing's Syndrome	85
MARKET REVENUE	85
<i>TABLE 19 GLOBAL SALES OF ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	86
<i>FIGURE 9 GLOBAL SALES OF ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2010-2017 (\$ MILLIONS)</i>	86
MARKET SHARES	87
<i>TABLE 20 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY AREA OF MEDICAL APPLICATION, 2011 (%)</i>	87
<i>FIGURE 10 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY AREA OF MEDICAL APPLICATION, 2011 (%)</i>	87
CHAPTER 6 MARKET ANALYSIS OF BIOLOGICAL ORPHAN DRUGS	89
MARKET FOR BIOLOGICAL ORPHAN DRUGS BY TYPE	90
MARKET OVERVIEW	90
Nplate (Romiplostim)	90

<b>TOPIC</b>	<b>PAGE NO.</b>
Fabrazyme (Agalsidase Beta)	91
Lumizyme/Myozyme (Alglucosidase Alfa)	91
Nulojix (Belatacept)	91
Avastin (Bevacizumab)	91
Ilaris (Canakinumab)	91
Sensipar (Cinacalcet)	91
Epogen/Procrit (Epoetin Alfa)	92
Enbrel (Etanercept)	92
Neupogen/Imumax (Filgrastim) and Neutroval (Tbo-filgrastim)	92
Gammagard Liquid (Immune Globulin Infusion [Human])	92
Remicade (Infliximab)	92
Multiferon (Interferon Alpha)	93
Avonex/Rebif (Interferon Beta-1a)	93
Yervoy (Ipilimumab)	93
Rituxan/MabThera (Rituximab)	93
Herclon/Herceptin (Trastuzumab)	94
VariZIG (Varicella Zoster Immune Globulin)	94
<b>MARKET REVENUE</b>	94
Fabrazyme (Agalsidase Beta)/Myozyme (Alglucosidase Alfa)	94
Nulojix (Belatacept)	94
Avastin (Bevacizumab)	95
Ilaris (Canakinumab)	95
Sensipar (Cinacalcet)	95
Epogen (Epoetin Alfa)	95
Enbrel (Etanercept)	95
Neupogen/Imumax (filgrastim) and Neutroval (Tbo-filgrastim)	95
Immune Globulin Infusions	96
Remicade (Infliximab)	96
Interferon Alfa and Interferon Beta	96
Yervoy (Ipilimumab)	96
Ribavirin USP and Rituxan (Rituximab)	96
VariZIG (Varicella Zoster Immune Globulin [Human])	97
Nplate (Romiplostim)	97
Herclon/Herceptin (Trastuzumab)	97
"Others" Segment	97
<i>TABLE 21 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	98
<i>FIGURE 11 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	98
<b>MARKET SHARES</b>	99
<i>TABLE 22 GLOBAL MARKET SHARES OF SALES OF MAJOR BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)</i>	100
<i>FIGURE 12 GLOBAL MARKET SHARES OF SALES OF MAJOR BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)</i>	101
<b>MARKET BY REGION</b>	101
<b>MARKET OVERVIEW</b>	102
<b>MARKET REVENUE</b>	103

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 23 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	104
<i>FIGURE 13 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)</i>	104
MARKET SHARES	104
<i>TABLE 24 GLOBAL MARKET SHARES OF SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)</i>	105
<i>FIGURE 14 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)</i>	105
MARKETS BY APPLICATIONS	105
<i>TABLE 25 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	106
<i>FIGURE 15 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2010-2017 (\$ MILLIONS)</i>	106
NEPHROLOGY AND INFECTIOUS DISEASES	106
Nulojix (Belatacept)	107
Sensipar/Mimpara (Cinacalcet)	107
Nplate (Romiplostim)	107
Market Revenue	108
<i>TABLE 26 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEPHROLOGY AND TO TREAT INFECTIOUS DISEASES BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	108
<i>FIGURE 16 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEPHROLOGY AND TO TREAT INFECTIOUS DISEASES BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	108
NEUROLOGY	109
Avonex/Avonex Pen (Interferon Beta)	109
Gammagard Liquid 10%/Kiovig [Immune Globulin Infusion (Human)]	110
Market Revenue	110
<i>TABLE 27 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	111
<i>FIGURE 17 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	111
ONCOLOGY	111
Neulasta (Pegfilgrastim)/Neupogen (Filgrastim)	111
Elitek (Rasburicase)	112
Nplate (Romiplostim)	112
Rituxan (Rituximab)	113
Herceptin (Trastuzumab)	113
Yervoy (Ipilimumab)	113
Xgeva (Denosumab)	114
Avastin (Bevacizumab)	114
Market Revenue	114
<i>TABLE 28 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	115
<i>FIGURE 18 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	116
MARKET FOR DRUGS USED IN THE "OTHERS" SEGMENT	116
Enbrel (Etanercept)	116
Lumizyme/Myozyme (Alglucosidase Alfa)	116

<b>TOPIC</b>	<b>PAGE NO.</b>
Rituxan (Rituximab)	117
Fabrazyme (Agalsidase Beta)	117
VariZIG [Varicella Zoster Immune Globulin (Human)]	118
MARKET REVENUE	118
<i>TABLE 29 GLOBAL SALES OF BIOLOGICAL DRUGS USED TO TREAT OTHER DISEASES BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	118
<i>FIGURE 19 GLOBAL SALES OF BIOLOGICAL DRUGS USED TO TREAT OTHER DISEASES BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	119
MARKET SHARES	119
<i>TABLE 30 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)</i>	120
<i>FIGURE 20 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)</i>	120
INDUSTRY STRUCTURE	120
MARKET LEADERS	120
<i>TABLE 31 MAJOR MANUFACTURERS OF BIOLOGICAL ORPHAN DRUGS</i>	121
MARKET SHARES	121
<i>TABLE 32 MANUFACTURER SHARES OF THE GLOBAL MARKET FOR BIOLOGICAL ORPHAN DRUGS, 2011 (%)</i>	122
<i>FIGURE 21 MANUFACTURER SHARES OF THE MARKET FOR BIOLOGICAL ORPHAN DRUGS, 2011 (%)</i>	122
CHAPTER 7 MARKET ANALYSIS OF NONBIOLOGICAL ORPHAN DRUGS	124
MARKET FOR NONBIOLOGICAL ORPHAN DRUGS	124
MARKET OVERVIEW	124
Recently Approved Nonbiological Orphan Drugs	125
Afinitor (Everolimus)	125
Sirturo (Bedaquiline)	125
Cystaran (Cysteamine Ophthalmic Solution)	125
Vidaza (Azacitidine)	125
Onfi (Clobazam)	126
NovoSeven (Coagulation Factor VIIa Recombinant)	126
Xalkori (Crizotinib)	126
Votrient (Pazopanib)	126
Ampyra/Fampyra (Dalfampridine)	126
Sprycel (Dasatinib)	127
Exjade (Deferasirox)	127
Zortress/Afinitor/Certican (Everolimus)	127
Aromasin (Exemestane)	127
Gleevec/Glivec (Imatinib Mesylate)	128
Cerezyme (Imiglucerase)	128
Lamictal (Lamotrigine)	128
Thalomid (Thalidomide)	128
Revlimid (Lenalidomide)	128
Tasigna (Nilotinib)	129
Istodax (Romidepsin)	129
Somatropin Recombinant Human Growth Hormone	129
Nexavar (Sorafenib)	129
Temodar (Temozolomide)	130



<b>TOPIC</b>	<b>PAGE NO.</b>
Thyrogen (Thyrotropin Alfa for Injection)	130
TOBI Podhaler (Tobramycin)	130
Zometa/Zomera/Aclasta/Reclast (Zoledronic or Zoledronate)	130
<b>MARKET REVENUE</b>	<b>131</b>
Vidaza (Azacitidine)	131
NovoSeven (Coagulation Factor VIIa Recombinant)	131
Onfi (Clobazam) and Xalkori (Crizotinib)	131
Dalfampridine and Deferasirox	131
Sprycel (Dasatinib)	131
Exjade (Deferasirox)	131
Gleevec/Glivec (Imatinib Mesylate)	132
Afinitor (Everolimus)	132
Aromasin (Exemestane)	132
Cerezyme (Imiglucerase)	132
Revlimid (Lenalidomide)	132
Votrient (Pazopanib)	132
Lamictal (Lamotrigine)	132
Tasigna (Nilotinib)	133
Pazopanib	133
Romidepsin	133
Somatropin and Sorafenib	133
Topamax (Topiramate)	133
TOBI Podhaler (Tobramycin)	133
Thalomid (Thalidomide)	133
Temozolomide	134
Zometa (Zoledronic)	134
Thyrogen (Thyrotropin Alfa)	134
<i>TABLE 33 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	134
<i>FIGURE 22 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	135
<b>MARKET SHARES</b>	<b>136</b>
<i>TABLE 34 GLOBAL MARKET SHARES OF SALES OF MAJOR NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)</i>	136
<i>FIGURE 23 GLOBAL MARKET SHARES OF SALES OF MAJOR NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)</i>	136
<b>MARKET BY REGION</b>	<b>137</b>
<b>MARKET OVERVIEW</b>	<b>138</b>
<b>MARKET REVENUE</b>	<b>140</b>
<i>TABLE 35 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	140
<i>FIGURE 24 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)</i>	140
<b>MARKET SHARES</b>	<b>141</b>
<i>TABLE 36 GLOBAL MARKET SHARES OF SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)</i>	141
<i>FIGURE 25 GLOBAL MARKET SHARES OF SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)</i>	141
<b>MARKET BY AREA OF MEDICAL APPLICATION</b>	<b>141</b>

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 37 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	142
<i>FIGURE 26 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2010-2017 (\$ MILLIONS)</i>	142
BLOOD-RELATED DISORDERS AND CYSTIC FIBROSIS	142
Ilaris (Canakinumab)	143
Exjade (Deferasirox)	143
Market Revenues	144
<i>TABLE 38 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED TO TREAT BLOOD-RELATED DISORDERS AND CYSTIC FIBROSIS BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	145
<i>FIGURE 27 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED TO TREAT BLOOD-RELATED DISORDERS AND CYSTIC FIBROSIS BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	145
NEUROLOGY	145
Market Revenue	146
<i>TABLE 39 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	146
<i>FIGURE 28 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	146
ONCOLOGY	147
Market Revenue	150
<i>TABLE 40 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	151
<i>FIGURE 29 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	151
OTHERS	152
Market Revenue	153
<i>TABLE 41 GLOBAL SALES OF NONBIOLOGICAL DRUGS USED TO TREAT DISEASES IN THE "OTHERS" CATEGORY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)</i>	154
<i>FIGURE 30 GLOBAL SALES OF NONBIOLOGICAL DRUGS USED TO TREAT DISEASES IN THE "OTHERS" CATEGORY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)</i>	154
MARKET SHARES	154
<i>TABLE 42 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)</i>	155
<i>FIGURE 31 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)</i>	155
INDUSTRY STRUCTURE	155
MARKET LEADERS	155
<i>TABLE 43 MAJOR MANUFACTURERS OF NONBIOLOGICAL ORPHAN DRUGS</i>	156
MARKET SHARES	156
<i>TABLE 44 MANUFACTURER SHARES OF THE MARKET FOR NONBIOLOGICAL ORPHAN DRUGS, 2011 (%)</i>	157
<i>FIGURE 32 MANUFACTURER SHARES OF THE MARKET FOR NONBIOLOGICAL ORPHAN DRUGS, 2011 (%)</i>	157
CHAPTER 8 PATENT ANALYSIS	159
PATENTS BY YEAR	159
<i>TABLE 45 NUMBER OF U.S. PATENTS FOR ORPHAN DRUGS BY YEAR, 2008 TO FEB. 2013</i>	160

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 33 NUMBER OF U.S. PATENTS FOR ORPHAN DRUGS BY YEAR, 2008 TO FEB. 2013</i>	160
PATENTS BY CATEGORY	160
<i>TABLE 46 NUMBER OF U.S. PATENTS FOR ORPHAN DRUGS BY MAJOR CATEGORY, 2008 TO FEB. 2013</i>	160
<i>FIGURE 34 NUMBER OF PATENTS FOR U.S. ORPHAN DRUGS BY MAJOR CATEGORY, 2008 TO FEB. 2013</i>	161
PATENTS BY COUNTRY	161
<i>TABLE 47 NUMBER OF U.S. ORPHAN DRUG PATENTS BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013</i>	161
<i>FIGURE 35 NUMBER OF U.S. ORPHAN DRUG PATENTS BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013</i>	162
<i>TABLE 48 U.S. ORPHAN DRUG PATENT SHARES BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013 (NO. OF PATENTS/%)</i>	162
<i>FIGURE 36 U.S. ORPHAN DRUG PATENT SHARES BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013 (%)</i>	162
PATENTS BY COMPANY	163
<i>TABLE 49 U.S. ORPHAN DRUG PATENTS BY COMPANY, 2008 TO FEB. 2013 (NO.)</i>	163
PATENTS BY ASSIGNEE	164
<i>TABLE 50 U.S. PATENTS ISSUED FOR ORPHAN DRUGS BY TYPE OF ASSIGNEE, 2008 TO FEB. 2013 (NO.)</i>	164
<i>FIGURE 37 U.S. PATENTS ISSUED FOR ORPHAN DRUGS BY TYPE OF ASSIGNEE, 2008 TO FEB. 2013</i>	164
CHAPTER 9 CURRENT SITUATION	167
CHAPTER 10 COMPANY PROFILES	172
ACORDA THERAPEUTICS	172
AEGERION PHARMACEUTICALS	172
ALEXION PHARMACEUTICALS	172
AMGEN INC.	173
ARIAD PHARMACEUTICALS	173
ASTRAZENECA PHARMACEUTICAL LP	174
BAXTER INTERNATIONAL	174
BAYER SCHERING	174
BRISTOL-MYERS SQUIBB	176
CANGENE BIOPHARMA	177
CELGENE CORP.	177
EXELIXIS	178
GENENTECH INC.	179
GENZYME	179
GLAXOSMITHKLINE	180
HYPERION THERAPEUTICS	181
JANSSEN RESEARCH & DEVELOPMENT, LLC	182
JOHNSON & JOHNSON	182
LUNDBECK	183
MERCK	183
NOVARTIS PHARMACEUTICALS	184
NOVO NORDISK	186

<b>TOPIC</b>	<b>PAGE NO.</b>
NPS PHARMACEUTICALS	186
ONYX THERAPEUTICS	187
PFIZER	187
RARE DISEASE THERAPEUTICS	188
ROCHE	189
SANOFI	190
SEATTLE GENETICS	191
SHIRE ORPHAN THERAPIES	191
SIGMA-TAU PHARMACEUTICALS INC.	192
SWEDISH ORPHAN BIOVITRUM AB (SOBI)	192
TALON THERAPEUTICS	192

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL SALES OF ORPHAN DRUGS BY TYPE, THROUGH 2017 (\$ MILLIONS)	8
TABLE 1 HISTORY OF ORPHAN DRUG LEGISLATION	11
TABLE 2 U.S. ORPHAN DRUG ACT, AMENDMENTS AND OTHER LEGISLATION	13
TABLE 3 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2012	14
TABLE 4 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN	19
TABLE 5 BIOLOGICAL ORPHAN DRUGS BY TRADE NAME AND INDICATION	21
TABLE 6 NONBIOLOGICAL ORPHAN DRUGS BY TRADE NAME AND INDICATION	22
TABLE 7 EXAMPLES OF ORPHAN DRUGS, INDICATIONS AND PREVALENCE OF DISEASES	27
TABLE 8 COMPANIES WITH MORE THAN FIVE ORPHAN DRUG APPROVALS,* 1983-2012	30
TABLE 9 ORPHAN DRUG MARKETING APPROVALS, 2008 THROUGH FEB. 2013	37
TABLE 10 ORPHAN DRUG SAFETY ALERTS AND RECALLS, 2008-2013	52
TABLE 11 GLOBAL SALES OF ORPHAN DRUGS BY TYPE, THROUGH 2017 (\$ MILLIONS)	64
TABLE 12 GLOBAL MARKET SHARES OF MAJOR ORPHAN DRUGS BY TYPE, 2011 (%)	65
TABLE 13 GLOBAL SALES OF ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)	68
TABLE 14 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY REGION, 2011 (%)	69
TABLE 15 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)	70
TABLE 16 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)	71
TABLE 17 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)	73
TABLE 18 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)	74
TABLE 19 GLOBAL SALES OF ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, THROUGH 2017 (\$ MILLIONS)	86
TABLE 20 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY AREA OF MEDICAL APPLICATION, 2011 (%)	87
TABLE 21 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	98
TABLE 22 GLOBAL MARKET SHARES OF SALES OF MAJOR BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)	100
TABLE 23 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)	104
TABLE 24 GLOBAL MARKET SHARES OF SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)	105
TABLE 25 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, THROUGH 2017 (\$ MILLIONS)	106
TABLE 26 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEPHROLOGY AND TO TREAT INFECTIOUS DISEASES BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	108
TABLE 27 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	111
TABLE 28 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	115

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 29 GLOBAL SALES OF BIOLOGICAL DRUGS USED TO TREAT OTHER DISEASES BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	118
TABLE 30 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)	120
TABLE 31 MAJOR MANUFACTURERS OF BIOLOGICAL ORPHAN DRUGS	121
TABLE 32 MANUFACTURER SHARES OF THE GLOBAL MARKET FOR BIOLOGICAL ORPHAN DRUGS, 2011 (%)	122
TABLE 33 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	134
TABLE 34 GLOBAL MARKET SHARES OF SALES OF MAJOR NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)	136
TABLE 35 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2017 (\$ MILLIONS)	140
TABLE 36 GLOBAL MARKET SHARES OF SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)	141
TABLE 37 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, THROUGH 2017 (\$ MILLIONS)	142
TABLE 38 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED TO TREAT BLOOD-RELATED DISORDERS AND CYSTIC FIBROSIS BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	145
TABLE 39 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	146
TABLE 40 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	151
TABLE 41 GLOBAL SALES OF NONBIOLOGICAL DRUGS USED TO TREAT DISEASES IN THE "OTHERS" CATEGORY BY ACTIVE INGREDIENT, THROUGH 2017 (\$ MILLIONS)	154
TABLE 42 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)	155
TABLE 43 MAJOR MANUFACTURERS OF NONBIOLOGICAL ORPHAN DRUGS	156
TABLE 44 MANUFACTURER SHARES OF THE MARKET FOR NONBIOLOGICAL ORPHAN DRUGS, 2011 (%)	157
TABLE 45 NUMBER OF U.S. PATENTS FOR ORPHAN DRUGS BY YEAR, 2008 TO FEB. 2013	160
TABLE 46 NUMBER OF U.S. PATENTS FOR ORPHAN DRUGS BY MAJOR CATEGORY, 2008 TO FEB. 2013	160
TABLE 47 NUMBER OF U.S. ORPHAN DRUG PATENTS BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013	161
TABLE 48 U.S. ORPHAN DRUG PATENT SHARES BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013 (NO. OF PATENTS/%)	162
TABLE 49 U.S. ORPHAN DRUG PATENTS BY COMPANY, 2008 TO FEB. 2013 (NO.)	163
TABLE 50 U.S. PATENTS ISSUED FOR ORPHAN DRUGS BY TYPE OF ASSIGNEE, 2008 TO FEB. 2013 (NO.)	164

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL SALES OF ORPHAN DRUGS BY TYPE, 2010-2017 (\$ MILLIONS)	8
FIGURE 1 GLOBAL SALES OF ORPHAN DRUGS BY TYPE, 2010-2017 (\$ MILLIONS)	64
FIGURE 2 GLOBAL MARKET SHARES OF MAJOR ORPHAN DRUGS BY TYPE, 2011 (%)	65
FIGURE 3 GLOBAL SALES OF ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)	68
FIGURE 4 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY REGION, 2011 (%)	69
FIGURE 5 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)	71
FIGURE 6 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)	71
FIGURE 7 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)	74
FIGURE 8 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUG SALES BY REGION, 2011 (%)	74
FIGURE 9 GLOBAL SALES OF ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2010-2017 (\$ MILLIONS)	86
FIGURE 10 GLOBAL MARKET SHARES OF ORPHAN DRUG SALES BY AREA OF MEDICAL APPLICATION, 2011 (%)	87
FIGURE 11 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	98
FIGURE 12 GLOBAL MARKET SHARES OF SALES OF MAJOR BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)	101
FIGURE 13 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)	104
FIGURE 14 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)	105
FIGURE 15 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2010-2017 (\$ MILLIONS)	106
FIGURE 16 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEPHROLOGY AND TO TREAT INFECTIOUS DISEASES BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	108
FIGURE 17 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	111
FIGURE 18 GLOBAL SALES OF BIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	116
FIGURE 19 GLOBAL SALES OF BIOLOGICAL DRUGS USED TO TREAT OTHER DISEASES BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	119
FIGURE 20 GLOBAL MARKET SHARES OF BIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)	120
FIGURE 21 MANUFACTURER SHARES OF THE MARKET FOR BIOLOGICAL ORPHAN DRUGS, 2011 (%)	122
FIGURE 22 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	135
FIGURE 23 GLOBAL MARKET SHARES OF SALES OF MAJOR NONBIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, 2011 (%)	136
FIGURE 24 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2010-2017 (\$ MILLIONS)	140
FIGURE 25 GLOBAL MARKET SHARES OF SALES OF NONBIOLOGICAL ORPHAN DRUGS BY REGION, 2011 (%)	141
FIGURE 26 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2010-2017 (\$ MILLIONS)	142

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 27 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED TO TREAT BLOOD-RELATED DISORDERS AND CYSTIC FIBROSIS BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	145
FIGURE 28 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN NEUROLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	146
FIGURE 29 GLOBAL SALES OF NONBIOLOGICAL ORPHAN DRUGS USED IN ONCOLOGY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	151
FIGURE 30 GLOBAL SALES OF NONBIOLOGICAL DRUGS USED TO TREAT DISEASES IN THE "OTHERS" CATEGORY BY ACTIVE INGREDIENT, 2010-2017 (\$ MILLIONS)	154
FIGURE 31 GLOBAL MARKET SHARES OF NONBIOLOGICAL ORPHAN DRUGS BY AREA OF MEDICAL APPLICATION, 2011 (%)	155
FIGURE 32 MANUFACTURER SHARES OF THE MARKET FOR NONBIOLOGICAL ORPHAN DRUGS, 2011 (%)	157
FIGURE 33 NUMBER OF U.S. PATENTS FOR ORPHAN DRUGS BY YEAR, 2008 TO FEB. 2013	160
FIGURE 34 NUMBER OF PATENTS FOR U.S. ORPHAN DRUGS BY MAJOR CATEGORY, 2008 TO FEB. 2013	161
FIGURE 35 NUMBER OF U.S. ORPHAN DRUG PATENTS BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013	162
FIGURE 36 U.S. ORPHAN DRUG PATENT SHARES BY ASSIGNEE'S COUNTRY, 2008 TO FEB. 2013 (%)	162
FIGURE 37 U.S. PATENTS ISSUED FOR ORPHAN DRUGS BY TYPE OF ASSIGNEE, 2008 TO FEB. 2013	164